Article: article from journal or magazin.
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish. PDF type: Priority Report
Clinical trials have shown that strong tumor antigen-specific CD8 T-cell responses are difficult to induce but can be achieved for T-cells specific for melanoma differentiation antigens, upon repetitive vaccination with stable emulsions prepared with synthetic peptides and incomplete Freund's adjuvant. Here, we show in four melanoma patients that ex vivo detectable T-cells and thus strong T-cell responses can also be induced against the more universal cancer-testis antigens NY-ESO-1 and Mage-A10. Interestingly, all patients had ex vivo detectable T-cell responses against multiple antigens after serial vaccinations with three peptides emulsified in incomplete Freund's adjuvant. Antigen-specific T-cells displayed an activated phenotype and secreted IFNgamma. The robust immune responses provide a solid basis for further development of human T-cell vaccination.
Antigens, Neoplasm/immunology, CD8-Positive T-Lymphocytes/immunology, Cancer Vaccines/adverse effects, Cancer Vaccines/immunology, Cell Differentiation/immunology, Cross Reactions, Epitopes, T-Lymphocyte/immunology, HLA-A2 Antigen/immunology, Humans, Immunologic Memory, Lymphocyte Activation, MART-1 Antigen, Melanoma/immunology, Melanoma/therapy, Membrane Proteins/immunology, Neoplasm Proteins/immunology, Skin Neoplasms/immunology, Skin Neoplasms/therapy
Web of science
Last modification date